Biological Products, (No Diagnostic Substances)
| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| Matrix Capital Management Company, LP | 6.92M | $46.0M | 10.79% | -- | 2026-03-31 |
| Frazier Life Sciences Management, L.P. | 5.10M | $34.0M | 7.95% | -- | 2026-03-31 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 4.88M | $32.0M | 7.61% | -- | 2026-03-31 |
| Long Focus Capital Management, LLC | 4.62M | $30.0M | 7.20% | -- | 2026-03-31 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 4.37M | $29.0M | 6.82% | -- | 2026-03-31 |
| BlackRock, Inc. | 3.59M | $23.0M | 5.59% | +26.2K | 2026-03-31 |
| Medicxi Ventures Management (Jersey) Ltd | 3.04M | $20.0M | 4.74% | -- | 2026-03-31 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.24M | $15.0M | 3.50% | -- | 2026-03-31 |
| Nantahala Capital Management, LLC | 2.12M | $14.0M | 3.30% | -- | 2026-03-31 |
| FRANKLIN RESOURCES INC | 2.07M | $13.0M | 3.23% | -125.7K | 2026-03-31 |
